Drug Trial Radar · NCT06119958
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 27, 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.
Conditions
- Drug Drug Interaction
Interventions
DWC202313Drug
Experimental Drug 1
DWC202314Drug
Experimental Drug 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax,ss of DWC202313 and DWC202314Time frame: Up to 14 days
- AUCt,ss of DWC202313 and DWC202314Time frame: Up to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H Plus YANGJI Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.